Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis

Drug Metabolism and Disposition

Volumn 37, Issue 10, 2009, Pages 2061-2068

  Grabar, Petra Bohanec ^a   Grabnar, Iztok ^a   Rozman, Blaž ^b   Logar, Dušan ^b   Tomšič, Matija ^b   Šuput, Daša ^b   Trdan, Tina ^a   Mašič, Lucija Peterlin ^a   Mrhar, Aleš ^a   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; DRUG METABOLIZING ENZYME; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RHEUMATOID FACTOR; TERIFLUNOMIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LATEX AGGLUTINATION TEST; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SYNOVIAL MEMBRANE;

EID: 70349266805     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027482     Document Type: Article

References (29)

1. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, and Ingelman- Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659-669. (Pubitemid 37048569)
2. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, and Dolzan V (2008) Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 64:871-876.
3. Chan V, Charles BG, and Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60:257-264. (Pubitemid 41224133)
4. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, and Goldstein JA (1994a) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598. (Pubitemid 24334747)
5. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422. (Pubitemid 24982362)
6. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361. (Pubitemid 28109566)
7. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387. (Pubitemid 40719266)
8. Herman D, Dolzan V, and Breskvar K (2003) Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdrav Vestn 72:347-351. (Pubitemid 36861352)
9. Kalgutkar AS, Nguyen HT, Vaz AD, Doan A, Dalvie DK, McLeod DG, and Murray JC (2003) In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active α-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 31:1240-1250. (Pubitemid 37152975)
10. Kunkel G and Cannon GW (2006) Leflunomide in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2:17-31.
11. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, and Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247-254. (Pubitemid 46768608)
12. Li J, Yao HW, Jin Y, Zhang YF, Li CY, Li YH, and Xu SY (2002) Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 23:551-555. (Pubitemid 34602097)
13. Lindbom L, Pihlgren P, Jonsson EN, and Jonsson N (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257. (Pubitemid 41196689)
14. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, and Campion G (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38:1595-1603.
15. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098.
16. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, Bertilsson L, Ingelman-Sundberg M, and Eliasson E (2008) Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol 64:1175-1179.
17. Rozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41:421-430.
18. Rudberg I, Hermann M, Refsum H, and Molden E (2008) Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 64:1181-1188.
19. Sachse C, Brockmöller J, Bauer S, and Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449. (Pubitemid 29161279)
20. Schmidt A, Schwind B, Gillich M, Brune K, and Hinz B (2003) Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed Chromatogr 17:276-281. (Pubitemid 36818150)
21. Shi J, Kovacs SJ, Wang Y, Ludden TM, and Bhargava VO (2005) Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J Pharmacokinet Pharmacodyn 32:419-439. (Pubitemid 41738434)
22. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113. (Pubitemid 43069582)
23. Skarke C, Kirchhof A, Geisslinger G, and Lötsch J (2005) Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol 61:887-892. (Pubitemid 41803698)
24. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, and Rosenburg R (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259-266. (Pubitemid 29088117)
25. Tiilikainen A, Fischer G, Grubic Z, Gyodi E, Ivaskova E, Jungerman M, Kastelan A, Korinkova P, Martinovic I, Sochnevs A, et al. (1997) Anthropological features of the East European region, in HLA: Genetic Diversity of HLA Functional and Medical Implication. Proceedings of the 12th International Histocompatibility Workshop and Conference (Charron D ed) pp 307-313, EDK, Medical and Scientific International Publisher, Paris.
26. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, Houtman PM, and Brouwers JR (2005) Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:569-574. (Pubitemid 40469086)
27. van Roon EN, Yska JP, Raemaekers J, Jansen TL, van Wanrooy M, and Brouwers JR (2004) A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. J Pharm Biomed Anal 36:17-22. (Pubitemid 39209403)
28. Vidan-Jeras B, Jurca B, Dolzan V, Jeras M, Breskvar K and Bohinjec M (1998) Caucasian Slovenian normal, in HLA 1998 (Gjertson D and Terasaki P eds) pp 180-181, American Society for Histocompatibility and Immunogenetics, Lenexa, KS.
29. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, and Strand V (1999) Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42:1322-1328. (Pubitemid 30265588)